• Smartmix TM One Step Reconstitution

    Technical Features : Fewer steps than comparable pre-filled options Utilizes standard drug vial configurations Self contained and compact sterile system Vented for easy and complete drug withdrawal Intuitive Visual indication of proper mix1 Usage Push device down to actuate, mixing with drug Pull up plunger, aspirating mixed drug into syringe Disconnect syringe from device
  • Mondi produces and donates protective medical gowns for key health care workers in Germany

    • Three Mondi plants in Germany (Halle, Steinfeld and Gronau) are set to produce and donate 10,000 protective gowns to workers in local nursing homes and retirement facilities
    • The initiative will involve using extruded PE tubes to be assembled into single-use protective garments

    15 May 2020 – Mondi, leading global packaging and paper group, has contributed material and processing expertise to produce plastic protective gowns for staff at local nursing homes and retirement facilities in order to help mitigate the spread of the COVID-19 pandemic in Germany.

  • EU actions to support availability of medicines during COVID-19 pandemic – update #5

    The EU Executive Steering Group on Shortages of Medicines Caused by Major Events held a virtual meeting on 6 May 2020. Participation to the meeting of the Executive Steering Group was extended to all the heads of the national competent authorities (NCAs) of EU Member States to discuss additional actions by EU authorities to ensure the continued availability of medicines in Europe during the ongoing COVID-19 pandemic.
  • EMA recommends expanding remdesivir compassionate use to patients not on mechanical ventilation

    In addition to patients undergoing invasive mechanical ventilation, the compassionate use recommendations now cover the treatment of hospitalised patients requiring supplemental oxygen, non-invasive ventilation, high-flow oxygen devices or ECMO (extracorporeal membrane oxygenation). The updated recommendations are based on preliminary results from the NIAID-ACTT study, which suggest a beneficial effect of remdesivir in the treatment of hospitalised patients with severe COVID-19. EMA is currently evaluating these data in the context of the rolling review of remdesivir. In addition, a treatment duration of 5 days has been introduced alongside the longer 10-day course, based on preliminary results from another study (GS-US-540-5773) suggesting that for patients not requiring mechanical ventilation or ECMO, the treatment course may be shortened from 10 to 5 days without any loss of efficacy. Patients who receive a 5-day treatment course but do not show clinical improvement will be eligible to continue receiving remdesivir for an additional 5 days. The option to shorten treatment duration also means that more patients may be able to receive the medicine, which is in very high demand worldwide. Although remdesivir is not yet authorised for marketing in the European Union, these recommendations for compassionate use will help some patients with severe COVID-19 access the medicine while EMA evaluates data on its benefits and risks. When the evaluation is complete, EMA will make a recommendation on whether or not remdesivir should receive a marketing authorisation. More information is available in the PDF iconsummary on compassionate use and the PDF iconconditions of use of remdesivir. More about the medicine Remdesivir is an antiviral medicine which is being investigated for the treatment of COVID-19. Remdesivir is a ‘viral RNA polymerase inhibitor’ (a medicine that interferes with the production of viral genetic material, preventing the virus from multiplying). It has shown broad in vitro activity against different RNA viruses, including SARS-CoV-2 and was originally developed for the treatment of Ebola virus disease. Remdesivir is being developed by Gilead Sciences Ireland CU and is given by infusion (drip) into a vein. More about the procedure National competent authorities can ask EMA for an opinion on how to administer, distribute and use certain medicines for compassionate use under Article 83 of Regulation (EC) No 726/2004. Compassionate use programmes enable patients to gain access to unauthorised medicines in emergency situations. This complements the possibility to enroll patients in ongoing clinical trials.
  • Contec, Inc., Milliken partner to produce Sporicidin® brand disinfectant qualified to kill coronavirus

    -- Leading manufacturers work to fill high demand for antibacterial cleaning solutions

    Our priorities have not changed, we focus on keeping our employees safe for their own health. At the same time it is the best guarantee to minimise any negative impact on business continuity. I am therefore happy to confirm that until now the interruptions have been limited. This would certainly not have been the case if we would not have taken pro-active measures as soon as practical. Despite all the actions we have taken, our overall output has been somewhat affected where we have had to reduce staffing levels, mainly due to quarantine regulations imposed by the Turkish Ministry of Health for employees with higher health risks. In combination with a significant increase in demand, this has resulted in longer lead times for some products of at least one week extra. We apologise for any inconvenience this is causing. We are working hard to overcome these issues, but it is realistic to assume that this situation will continue for several more weeks. With respect to the weekend curfews which have been announced in Turkey for the remainder of April, we have received the confirmation from the Internal Affairs that as a supplier of both the healthcare and food industry we will be exempt. Our employees will therefore be allowed to travel to work also during the weekends and our operations will continue to produce as normal. We will monitor the situation continuously and will keep you informed of future evolutions. Please do not hesitate to contact your local Korozo contact, if you have any further questions. We appreciate your support and cooperation and we wish you all healthy and safe days.
  • Increased Options for Dispensing Solutions

    Hand sanitizer is not the only product facing high demand. According to Euromonitor2 International, the food market is anticipated to grow at a rate of 3.5% by 2024 in the sauces, dressings, and condiments segments. Consumers are turning to items like shelf-stable foods and other products of necessity. After the acquisition of RPC Group in July of 2019, our Company expanded its portfolio of dispensing closures. Growth within this market enables us to provide a wide array of options for consumers desiring products of importance. In addition, we are currently accelerating our innovative efforts within this space to offer more sizes and orifice options for dispensing and flip-top closures based on recent consumer demand. Our flip-top closures range from 15mm to 53mm with various orifice size and value options. Our flip-top tamper-evident closure, FlipGuard, is another option that can serve the food and home care markets.
  • A novel Dual-Temperature Thermal packaging solution for the bio-pharmaceutical sector

    Packaging Technology Group has recently expanded it TRUEtemp Naturals® line of cellulose packaging products with the addition of a dual-temperature packaging solution. This first-of-its-kind sustainable packaging allows medications with different temperature requirements to be packaged and carried in the same container. Not only does this shipper preserve the efficacy of thermally-sensitive drugs, but it also provides a more sustainable option to carefully protect and transport medications. The ability to co-contain medicines with varying temperature profiles will surely reduce the amount of material used for packaging itself. This, furthermore, will also save on shipping costs and assembly training and make medication slightly more affordable. Based on PTG’s S4 value proposition, which states their aim to provide Simple, Small, Sustainable and affordable Shipping Solutions, the TRUEtemp Naturals® Cellulose Shippers are: • Made from 100% recycled paper, wood and corrugate • Curbside recyclable, repulpable and biodegradable • EPS equivalent in insulation value The dual temperature property in addition to the existing benefits of the line make the new product truly innovative and sustainable. Currently being applied primarily in the bio-pharmaceutical sector for medicines, this technology can potentially be exposed to other sectors to improve product integrity and promote sustainability.
  • Multilingual and compact: Schreiner MediPharm supplies booklet labels for clinical studies from Sanofi

    Accuracy, safety, efficiency and speed are essential for successful clinical trials. Since the studies are mainly carried out internationally, the investigational medicinal products must be reliably labeled and have all the important information in several languages. Sanofi needed a multi-page label for this, on which the product information is available in many different languages. In addition, it should adhere firmly to the plastic needle protection system and should not affect the functionality of the system. The booklet label developed by Schreiner MediPharm is wrapped closely around the needle protection system. The compact booklet comprises 32 pages with medication information in 22 languages. It adheres reliably to the plastic base of the needle protection system and can be easily wrapped around the square device thanks to the flexible material construction made of thin booklet paper plus layers of film. A grip tab allows the label to be opened and closed comfortably. The booklet label is partially attached to the device so that the pre-filled syringe and its contents are clearly visible after it has been opened. In order to be able to remove the booklet before the injection, it is equipped with a perforation - only a small part of the label, which can contain variable data, for example, remains on the device afterwards. The Schreiner MediPharm Clinical Trial Supplies (CTS) team is a competence and service partner for clinical studies. It has extensive expertise in the field of clinical trial supplies and advises all customers individually and flexibly according to their needs. A specialized process center for booklet labels creates reliable solutions that are optimally adapted to the respective packaging of the investigational medicinal products. About Sanofi Sanofi is a global healthcare company headquartered in Paris with more than 100,000 employees. The group is represented in over 100 countries, with global sales of around 34.5 billion euros in 2018. More than 15,000 Sanofi employees on three continents research and develop new medicines and vaccines.
  • CPG talents meet the needs of the COVID-19 Crisis


    As part of PepsiCo’s ongoing efforts to provide relief to people and communities impacted by COVID-19, PepsiCo partnered with Product Ventures’ Prototyping and Realization Lab in Plano, Texas to provide face shields to healthcare workers. As local communities were reporting a shortage of personal protective equipment (PPE) to use in their fight against COVID-19, PepsiCo and the Product Ventures team were able to leverage their long-term relationship to quickly assemble the right people, resources, materials and equipment to address this issue. Volunteers from both companies convened at PepsiCo’s Plano lab facility, a sanitary, food-safe environment, to fabricate, package, and ship these face shields to local hospitals including the Lehigh Valley Hospital in Allentown, Pennsylvania, which is on the frontlines of responding to the pandemic.

    “We’re so grateful for our ongoing relationship with PepsiCo and are proud of the partnership demonstrated in response to this challenge,” said Peter Clarke, CEO and founder of Product Ventures. “Our designers regularly face condensed timelines and deliver quick and clever solutions to difficult problems, so we were uniquely positioned to react to this crisis and provide help.

    ” The team developed over 20 iterations of the design. Scalability was a driving factor in their design approach to ensure demand could be easily met. The co-lab’s design can be manufactured in high quantities using different gauges of PET in case of potential shortages. This adaptable approach maintains the scalability without compromising the protection of the face shield.

    The packaging design was given careful consideration early in the process to enable quick and easy distribution. One 12 in. x 14 in. x 6 in. box contains 120 flat face shields, more than four times the quantity in a box of standard face shields. This one box can be carried by a single person, allowing for easy and efficient access, distribution, and storage.

    This is just a small part of PepsiCo’s broader relief efforts, which include a commitment of more than $50 million focused on serving nutritious meals to people impacted by COVID-19 and providing vital support for healthcare workers, as well as testing and screening services.

    Face shields are being offered to medical professionals in Connecticut, Illinois, New Jersey, New York, Pennsylvania, and other states as needed. They are currently being manufactured in PepsiCo’s Plano, Texas and Barrington, Illinois locations. Between the two facilities, more than 2,000 face shields have already been produced and the team has the capability to quickly manufacture more if needed.

  • Pages